The invention relates to substituted tertiary-heteroalkylamine compounds useful
as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid trans:
protein-I) and compounds, compositions and methods for treating atherosclerosis
and other coronary artery disease.